Trial Profile

A Study to Assess the Safety, Tolerability, and Pharmacodynamics of Multiple Dose MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 17 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 5475 (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; Hypoxaemia
Focus Adverse reactions; Therapeutic Use
Acronyms MK-5475-009
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

12 Aug 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to business reasons.
16 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com